26/09/2022Published by Fondazione Gianni Bonadonna at 26/09/2022Categories Events UncategorizedBenefits of pralsetinib in patients with RET fusions
19/09/2022Published by Fondazione Gianni Bonadonna at 19/09/2022Categories Events UncategorizedOutcomes of neoadjuvant durvalumab in triple-negative breast cancer – Experts’ comment
14/09/2022Published by Fondazione Gianni Bonadonna at 14/09/2022Categories Events UncategorizedDosing of first three patients in the first-in-human study with selective N-glycosylation inhibitors
05/09/2022Published by Fondazione Gianni Bonadonna at 05/09/2022Categories Events UncategorizedPositive results with pembrolizumab in advanced triple-negative breast cancer
29/08/2022Published by Fondazione Gianni Bonadonna at 29/08/2022Categories Events UncategorizedCancer vaccines, present and future
22/08/2022Published by Fondazione Gianni Bonadonna at 22/08/2022Categories Events UncategorizedAmcenestrant in post-menopausal women with ER-positive/HER2-negative advanced breast cancer
01/08/2022Published by Fondazione Gianni Bonadonna at 01/08/2022Categories Events UncategorizedMore than 100.000 cases in the AACR Project GENIE
25/07/2022Published by Fondazione Gianni Bonadonna at 25/07/2022Categories Events UncategorizedDurable clinical benefits in lung cancer with a KRASG12C inhibitor
18/07/2022Published by Fondazione Gianni Bonadonna at 18/07/2022Categories Events UncategorizedA novel antibody-drug conjugate for metastatic breast cancer patients
